Neurocrine Biosciences | NBIX - Net Income



Neurocrine Biosciences reported $107.5M in Net Income for its fiscal quarter ending in June of 2025.


Net Income Change Date
AbbVie USD 938M 348M Jun/2025
Acadia Pharmaceuticals USD 26.67M 7.68M Jun/2025
Agios Pharmaceuticals USD -112020000 22.73M Jun/2025
ALKERMES USD 87.1M 64.63M Jun/2025
Alnylam Pharmaceuticals USD -66277000 8.8M Jun/2025
Amgen USD 1.43B 298M Jun/2025
Biogen USD 634.8M 394.3M Jun/2025
BioMarin Pharmaceutical USD 240.53M 54.85M Jun/2025
Cytokinetics USD -134370000 27.01M Jun/2025
Dynavax Technologies USD 18.72M 114.82M Jun/2025
Exelixis USD 230.42M 70.8M Jul/2025
Gilead Sciences USD 1.96B 645M Jun/2025
Halozyme Therapeutics USD 165.16M 47.06M Jun/2025
Incyte USD 405M 246.8M Jun/2025
Ionis Pharmaceuticals USD 123.55M 270.49M Jun/2025
Neurocrine Biosciences USD 107.5M 99.6M Jun/2025
Pfizer USD 2.91B 58M Jun/2025
Prothena USD -125770000 67.81M Jun/2025
Regeneron Pharmaceuticals USD 1.39B 582.9M Jun/2025
Repligen USD 14.87M 9.04M Jun/2025
Sarepta Therapeutics USD 196.89M 644.4M Jun/2025
Teva Pharmaceutical Industries USD 282M 68M Jun/2025
Ultragenyx Pharmaceutical USD -114951000 36.13M Jun/2025
Vertex Pharmaceuticals USD 1.03B 386.6M Jun/2025